title: The association of taxane resistance genes with the clinical course of ovarian carcinoma.
abstract: Taxane and platinum-based chemotherapy regimens are standard treatment for advanced ovarian carcinoma. Expression levels of putative markers of taxane resistance in carcinoma tissues and paired peritoneal samples (n=55) and in 16 samples of ovaries without signs of carcinoma were compared with clinical data and the patients' time to progression. KIF14, PRC1, CIT and ABCC1 genes were significantly overexpressed in carcinomas when compared with normal ovarian tissues, while ABCB1 and CASP9 expression was decreased. Associations of protein expression of the proliferation marker Ki-67 with KIF14, PRC1, ABCB1 and CASP2 were found. Lastly, it was discovered that ABCB1 and CASP2 levels associated with FIGO stage and that the CIT level associated with the time to progression of ovarian carcinoma patients (P<0.0001). In conclusion, ABCB1, CASP2, KIF14, PRC1 and CIT genes seem to associate with surrogate markers of ovarian carcinoma progression and CIT gene associates with therapy outcome.
authors.affiliation: Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
authors.forename: Marie
authors.initials: M
authors.lastname: Ehrlichova
authors.forename: Beatrice
authors.initials: B
authors.lastname: Mohelnikova-Duchonova
authors.forename: Jiri
authors.initials: J
authors.lastname: Hrdy
authors.forename: Veronika
authors.initials: V
authors.lastname: Brynychova
authors.forename: Marcela
authors.initials: M
authors.lastname: Mrhalova
authors.forename: Roman
authors.initials: R
authors.lastname: Kodet
authors.forename: Lukas
authors.initials: L
authors.lastname: Rob
authors.forename: Marek
authors.initials: M
authors.lastname: Pluta
authors.forename: Ivan
authors.initials: I
authors.lastname: Gut
authors.forename: Pavel
authors.initials: P
authors.lastname: Soucek
authors.forename: Radka
authors.initials: R
authors.lastname: Vaclavikova
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D020169:Caspases / Q000235:genetics; D018797:Cell Cycle Proteins / Q000235:genetics; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D016547:Kinesins / Q000235:genetics; D008875:Middle Aged; D015513:Oncogene Proteins / Q000235:genetics; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010053:Ovary / Q000378:metabolism; D010537:Peritoneum / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D018797:Cell Cycle Proteins; D047908:Intracellular Signaling Peptides and Proteins; D015513:Oncogene Proteins; C116662:PRC1 protein, human; D043823:Taxoids; C080625:taxane; C115635:citron-kinase; D017346:Protein Serine-Threonine Kinases; D020169:Caspases; C502598:KIF14 protein, human; D016547:Kinesins
keywords: Clinical course; Cytokinesis; Gene expression; Ovarian carcinoma; Resistance; Taxane